Compare Mesoblast Limited (MESO) vs Rent the Runway Inc (RENT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Rent the Runway Inc — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Rent the Runway Inc trades at $3.13 (market cap $104.26M). The key difference: Mesoblast Limited is far larger — about 20.8× Rent the Runway Inc's market cap, and Mesoblast Limited is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals.
| MESO | RENT | |
|---|---|---|
Market Cap | $2.17B | $104.26M |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $9.39 |
52-Week Low | $12.88 | $3.09 |
Enterprise Value | $2.17B | $264.36M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
RENT trades at $3.11, down 1.58% with a bearish technical signal. The company shows improving fundamentals with revenue growing to $306.20M in 2025 and narrowing losses from -$212M in 2022 to -$69.90M. Valuation metrics appear attractive with P/E of 0.42 and P/S of 0.17, while recent leadership changes and Q1 2026 revenue growth of 29.2% suggest operational momentum.
Despite deep negative equity and high debt levels, RENT's improving margin trends and analyst buy ratings (42% consensus) indicate potential upside. Key risks include persistent negative cash flow and competitive pressures in the rental fashion space. The stock presents a high-risk opportunity with valuation support if turnaround execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
